5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer

Journal of Gastrointestinal Surgery

Volumn 9, Issue 8, 2005, Pages 1068-1079

  Eisenberg, David P ^a   Adusumilli, Prasad S ^a   Hendershott, Karen J ^a   Yu, Zhenkun ^a   Mullerad, Michael ^a   Chan, Mei Ki ^a   Chou, Ting Chao ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Herpes simplex virus; NV1066; Synergism; Viral oncolysis

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCITABINE; ONCOLYTIC VIRUS;

ARTICLE; GENE THERAPY; GENE VECTOR; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOLOGY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VIRUS REPLICATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 27644575167     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2005.06.024     Document Type: Article

References (34)

1. A. Jemal, T. Murray, and E. Ward Cancer statistics, 2005 Ca Cancer J Clin 55 2005 10 30
2. R. Wolff, J. Abbruzzese, and D. Evans Neoplasms of the exocrine pancreas D. Kufe R. Pollock R. Weichselbaum Holland Frei Cancer Medicine 6th ed. 2003 BC Decker Canada
3. V.J. Picozzi, and L.W. Traverso The Virginia Mason approach to localized pancreatic cancer Surg Oncol Clin North Am 13 2004 663 674
4. R.J. Geer, and M.F. Brennan Prognostic indicators for survival after resection of pancreatic adenocarcinoma Am J Surg 165 1993 68 73
5. M.F. Brennan Adjuvant therapy following resection for pancreatic adenocarcinoma Surg Oncol Clin North Am 13 2004 555 566
6. T.M. Breslin, K.R. Hess, and D.B. Harbison Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration Ann Surg Oncol 8 2001 123 132
7. T.A. Sohn, C.J. Yeo, and J.L. Cameron Resected adenocarcinoma of the pancreas - 616 patients: Results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567 579
8. S.S. Nitecki, M.G. Sarr, T.V. Colby, and J.A. Van Heerden Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221 1995 59 66
9. S. Andreansky, L. Soroceanu, and E.R. Flotte Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors Cancer Res 57 1997 1502 1509
10. R. Chambers, G.Y. Gillespie, and L. Soroceanu Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma Proc Natl Acad Sci U S A 92 1995 1411 1415
11. A. Chahlavi, T. Todo, R.L. Martuza, and S.D. Rabkin Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma Neoplasia 1 1999 162 169
12. S.J. Advani, S.M. Chung, and S.Y. Yan Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors Cancer Res 59 1999 2055 2058
13. T. Mineta, S.D. Rabkin, T. Yazaki, W.D. Hunter, and R.L. Martuza Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1 1995 938 943
14. P.F. McAuliffe, W.R. Jarnagin, P. Johnson, K.A. Delman, H. Federoff, and Y. Fong Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses J Gastrointest Surg 4 2000 580 588
15. R.J. Wong, S.H. Kim, J.K. Joe, J.P. Shah, P.A. Johnson, and Y. Fong Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus J Am Coll Surg 193 2001 12 21
16. J.J. Bennett, D.A. Kooby, and K. Delman Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer J Mol Med 78 2000 166 174
17. D.A. Kooby, J.F. Carew, and M.W. Halterman Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207) FASEB J 13 1999 1325 1334
18. T. Yazaki, H.J. Manz, S.D. Rabkin, and R.L. Martuza Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1 Cancer Res 55 1995 4752 4756
19. S.J. Advani, S.J. Chmura, and R.R. Weichselbaum Radiogenetic therapy: On the interaction of viral therapy and ionizing radiation for improving local control of tumors Semin Oncol 24 1997 633 638
20. S.J. Advani, G.S. Sibley, and P.Y. Song Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors Gene Ther 5 1998 160 165
21. S.F. Stanziale, H. Petrowsky, and J.K. Joe Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase Surgery 132 2002 353 359
22. J.J. Bennett, P. Adusumilli, and H. Petrowsky Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207) FASEB J 18 2004 1001 1003
23. R. Longnecker, S. Chatterjee, R.J. Whitley, and B. Roizman Identification of a herpes simplex virus 1 glycoprotein gene within a gene cluster dispensable for growth in cell culture Proc Natl Acad Sci U S A 84 1987 4303 4307
24. R.J. Wong, J.K. Joe, S.H. Kim, J.P. Shah, B. Horsburgh, and Y. Fong Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases Hum Gene Ther 13 2002 1213 1223
25. Y. Fong, N. Kemeny, and W. Jarnagin Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases Proc Am Soc Clin Oncol 21 2002 8a
26. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
27. T.C. Chou The median-effect principle and the combination index for quantitation of synergism and antagonism T.C.R. Chou Synergism and Antagonism in Chemotherapy 1991 Academic Press New York 61 102
28. Chou JCTC. Dose-effect analysis with microcomputers: Quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. Manual and Software. Cambridge, U.K.: Biosoft Cambridge; 1987.
29. J. Chou Quantitation of synergism and antagonism of two or more drugs by computerized analysis T.C. Chou D.C. Rideout Synergism and antagonism in chemotherapy 1991 Academic Press San Diego, CA 223 244
30. T.C. Chou, R.J. Motzer, Y. Tong, and G.J. Bosl Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design J Natl Cancer Inst 86 1994 1517 1524
31. T. Toyoizumi, R. Mick, A.E. Abbas, E.H. Kang, L.R. Kaiser, and K.L. Molnar-Kimber Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer Hum Gene Ther 10 1999 3013 3029
32. J.D. Bradley, Y. Kataoka, and S. Advani Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus Clin Cancer Res 5 1999 1517 1522
33. T. Todo, F. Feigenbaum, and S.D. Rabkin Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus Mol Ther 2 2000 588 595
34. S. Varghese, J.T. Newsome, and S.D. Rabkin Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates Hum Gene Ther 12 2001 999 1010